Liquidia Co. (NASDAQ:LQDA) Receives $26.63 Consensus PT from Analysts

Liquidia Co. (NASDAQ:LQDA - Get Free Report) has been assigned an average recommendation of "Buy" from the nine brokerages that are covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a hold recommendation, six have issued a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year target price among analysts that have covered the stock in the last year is $26.63.

A number of analysts have recently commented on LQDA shares. HC Wainwright reaffirmed a "buy" rating and set a $29.00 target price on shares of Liquidia in a report on Thursday, March 20th. Needham & Company LLC reaffirmed a "buy" rating and set a $25.00 price objective on shares of Liquidia in a research note on Thursday, April 10th. Finally, Scotiabank reissued an "outperform" rating on shares of Liquidia in a report on Thursday, March 20th.

Insider Transactions at Liquidia

In other news, insider Jason Adair sold 1,856 shares of Liquidia stock in a transaction on Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the transaction, the insider now owns 184,304 shares in the company, valued at $2,501,005.28. The trade was a 1.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, General Counsel Russell Schundler sold 5,964 shares of Liquidia stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $80,931.48. Following the transaction, the general counsel now directly owns 570,301 shares in the company, valued at $7,738,984.57. This trade represents a 1.03 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 33,128 shares of company stock valued at $450,072 over the last ninety days. Insiders own 30.10% of the company's stock.

Institutional Trading of Liquidia

Institutional investors and hedge funds have recently bought and sold shares of the stock. LM Advisors LLC acquired a new position in shares of Liquidia in the fourth quarter worth $25,948,000. Invesco Ltd. boosted its position in shares of Liquidia by 2,675.0% in the 4th quarter. Invesco Ltd. now owns 700,171 shares of the company's stock valued at $8,234,000 after purchasing an additional 674,940 shares during the period. Janus Henderson Group PLC boosted its holdings in shares of Liquidia by 1,484.5% in the fourth quarter. Janus Henderson Group PLC now owns 535,552 shares of the company's stock valued at $6,293,000 after acquiring an additional 501,752 shares during the period. Mirabella Financial Services LLP purchased a new position in Liquidia during the 4th quarter worth $5,880,000. Finally, Eversept Partners LP boosted its stake in shares of Liquidia by 314.1% during the fourth quarter. Eversept Partners LP now owns 571,305 shares of the company's stock worth $6,719,000 after buying an additional 433,356 shares during the period. 64.54% of the stock is currently owned by hedge funds and other institutional investors.

Liquidia Stock Up 3.3 %

Shares of Liquidia stock traded up $0.44 on Monday, reaching $13.99. 309,184 shares of the stock were exchanged, compared to its average volume of 962,074. The business has a 50 day moving average price of $14.49 and a two-hundred day moving average price of $12.85. The firm has a market capitalization of $1.19 billion, a price-to-earnings ratio of -8.57 and a beta of 0.23. Liquidia has a twelve month low of $8.26 and a twelve month high of $16.81.

Liquidia (NASDAQ:LQDA - Get Free Report) last posted its earnings results on Wednesday, March 19th. The company reported ($0.46) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.08). The business had revenue of $2.92 million for the quarter, compared to analyst estimates of $4.60 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. Research analysts forecast that Liquidia will post -1.51 EPS for the current year.

Liquidia Company Profile

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).